Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Practice Parameter: The Diagnostic Evaluation and Treatment of Trigeminal Neuralgia (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the AAN & EFNS
Neurol 71:1183-1190, Gronseth,G.,et al, 2008
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Efficacy and Tolerability for the New Antiepileptic Drugs I: Treatment of New Onset Epilepsy
Neurol 62:1252-1260, French,J.A.,et al, 2004
Efficacy and Tolerability of the New Antiepleptic Drugs II: Treatment of Refractory Epilepsy
Neurol 62:1261-1273, French,J.A.,et al, 2004
Practice Parameter: Treatment of the Child with a First Unprovoked Seizure
Neurol 60:166-175, Hirtz,D.,et al, 2003
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Practice Patterns of Neurologists Regarding Bone and Mineral Effefcts of Antiepileptic Drug Therapy
Arch Neurol 58:1369-1374,1352, Valmadrid,C.,et al, 2001
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Practice Parameter,Management Issues for Women with Epilepsy (Summary Statement)
Neurol 51:944-948, Rpt of the Quality Stnds Subcmte AAN, 1998
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994